Lipantil Micro

Fenofibrate, the active ingredient in Lipantil Micro, is a fibrate‑class lipid‑lowering agent presented as an oral tablet for oral administration. It is indicated for the management of elevated triglyceride and cholesterol levels in adult patients with various forms of dyslipidaemia.

GNH USA supplies Lipantil Micro as a licensed, Good Distribution Practice‑compliant pharmaceutical product, providing reliable global sourcing for hospitals, pharmacies and clinical centres worldwide, with consistent quality and regulatory compliance across EU markets, and a track record of timely delivery.

Fenofibrate acts on lipid metabolism pathways to reduce elevated blood lipids.

- Hypertriglyceridemia: reduces triglyceride levels and associated cardiovascular risk. - Mixed dyslipidemia: lowers triglycerides and modestly improves HDL cholesterol. - Hypercholesterolemia: decreases total and LDL cholesterol concentrations.

Fenofibrate may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Elevated liver enzymes: transient increase in ALT or AST. - Muscle pain: mild myalgia without weakness. - Headache: occasional tension‑type headache.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with possible renal impairment. - Hepatotoxicity: significant liver injury or jaundice. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Gallbladder disease: cholelithiasis or biliary colic.

When prescribing fenofibrate, clinicians should consider several safety and handling precautions.

- Liver function: assess baseline hepatic enzymes and monitor periodically. - Renal function: evaluate kidney status, especially in patients with impairment. - Muscle disorders: avoid in patients with active myopathy or recent rhabdomyolysis. - Drug interactions: review concomitant medications that affect statin metabolism. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Fenofibrate can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Statins (especially high‑dose simvastatin): increased risk of myopathy or rhabdomyolysis. - Anticoagulants (warfarin): potentiation of anticoagulant effect, requiring INR monitoring. - Bile acid sequestrants: may reduce fenofibrate absorption, diminishing lipid‑lowering effect.

Moderate Interactions (Monitor Closely): - CYP2C8 inhibitors (e.g., gemfibrozil): increased fenofibrate plasma levels. - Immunosuppressants (e.g., cyclosporine): may raise fenofibrate concentrations. - Thyroid hormones: fenofibrate may affect thyroid function tests.